Inclusion: dogs with a plexus tumor suspected after MRI/CT that is planned for surgical resection

Exclusion: overt metastatic disease, clear breach of the spinal cord

Inclusion criterium: dogs diagnosed with metastatic insulinoma (TNM stage II or III), or recurrent insulinoma

Exclusion criteria: dogs with TNM stage I insulinoma and dogs with systemic co-morbidities or other life-limiting diseases

All sinonasal tumours in dogs

All unoperated meningiomas in dogs

Inclusion criteria

• absence of metastatic disease
• tumours increasing in size under other treatments
• tumour size <1 cm and > 5 cm

Exclusion criteria

• Patients in which anaesthesia is contra-indicated
• Patients with decompensated cardiac disease
• Patients with cardiac hemangiosarcomas, lymphomas or metastases

Inclusion: cytological or histological diagnosis of urothelial carcinoma, conventional treatments (chemotherapies, targeted molecular therapies, surgery and radiotherapy) refused, not applicable or failed.

Exclusion: life expectancy of less than 1 month (linked or not to the tumour disease), general anaesthesia is contraindicated.

Inclusion criteria:

• dog diagnosed with osteosarcoma
• dog is eligible for surgical removal of the tumor

Inclusion criteria:

• Dogs diagnosed with any type of cancer that will receive doxorubicin-based therapy (e.g. CHOP, doxorubicine monotherapy, doxorubicine combi with carboplatin, ...) in consultation with a veterinary oncologist.

Exclusion criteria:

• Patients receiving positive inotropic drugs, such as pimobendan, digoxin, theophylline, catecholamines...
• Patients that have had any type of chemotherapy (e.g. Palladia, …) before the inclusion to the study (prednisolone is allowed) (exception can be made for CHOP protocol - please contact study investigators)
• Patients with systemic hypertension or patients receiving medication to control this (e.g. ACEi, telmisartan, amlodipine…)
• Patients with hypothyroidism (will not standardly be tested before inclusion, only when clinically suspected)
• Patients with chronic kidney disease
• Patients with clinically significant echocardiographic abnormalities at the beginning of the study

Inclusion criteria:

• Dog diagnosed with primary hepatocelullar carcinoma
• Metastases of hepatic tumours (up to 3 lesions)
• Size of lesions between 1 to 3 cm
• Normal hepatic function
• Dog can undergo general anesthesia

Exclusion criteria:

• Hepatic dysfunction
• Coagulopathies
• Systemic metastatic disease

Inclusion criteria:

• Primary hepatic tumour
• Liver metastases
• Normal hepatic function
• Absence of coagulopathies
• Patient can undergo general anaesthesia

Exclusion criteria:

• Untreatable primary tumour

Inclusion criteria: dogs diagnosed with mucosal melanoma who are deemed suitable candidates for surgical resection and/or radiation therapy targeting the primary tumour

Exclusion criteria: dogs in which the primary tumour is no longer available for vaccine preparation—for instance, cases where the tumour has already been surgically excised and formalin-fixed—are not eligible for inclusion in the trial

Inclusion criteria:

• Dogs suspected of having a meningioma